Quanterix narrows 2026 revenue outlook to $142M-$146M as Florida Medicaid sets $484 LucentAD reimbursement (NASDAQ:QTRX)

Quanterix (QTRX) updated its 2026 revenue outlook to $142M-$146M, narrowing from a previous range. This follows Florida Medicaid's decision to set a $484 reimbursement rate for LucentAD, a product by Quanterix. The company's revenue guidance is now more precise, which may impact investor expectations.

Original reporting
Published Nov 9, 2026, 5:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 5:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Quanterix narrows 2026 revenue outlook to $142M-$146M as Florida Medicaid sets $484 LucentAD reimbursement (NASDAQ:QTRX) — source image
Decision brief

The 30-second read

$QTRXBearishMed
01

Why it matters

The narrowed outlook signals tighter revenue expectations, likely prompting a short‑term price decline.

02

Market read

Guidance revisions are a primary catalyst for stock movement; traders may adjust positions accordingly.

03

What to watch

Potential upside from future contract wins or expanded reimbursement policies not reflected in current guidance.

Relevance 6/10Novelty 6/10Timing: post‑market release

Background

Quanterix is a diagnostic company whose revenue is tied to Medicaid reimbursement rates for its LucentAD test.

Company-level read

Ticker impact

$QTRXBearishHigh confidence
Context

Quanterix narrowed its 2026 revenue outlook to $142M-$146M, a fresh guidance update.

Expected impact

likely downside pressure as investors price in reduced revenue outlook

Evidence & confidence

Revenue guidance is a material metric; a downward revision typically triggers sell‑side sentiment.

Market effects

May weigh on other diagnostic and biotech firms with similar Medicaid reimbursement exposure.

Limited to U.S. biotech sector; no broad regional effect.

Minimal global impact beyond niche market participants.

Counterpoint

If the Medicaid reimbursement rate is higher than expected, the guidance cut could be overly conservative.

Key entities

  • Quanterix Corporation

    Provider of digital health diagnostic platforms.

Related articles

$QTRXMed

What Quanterix (QTRX) Said on Its Q3 Earnings Call

Quanterix (QTRX) reported a Q3 net loss of $21.6M, improved from last year. Adjusted EBITDA loss was $12.2M. Gross margin rose to 47.4%. LucentAD test volume doubled, but revenue from diagnostics fell to $1.2M. The company expects 2026 gross margin of 48-50% and $70M cash. Alzheimer's test discussions with FDA continue, with no clearance date given.

$QTRXMed

Quanterix Releases Financial Results for the Third Quarter of 2026

Quanterix Corp (QTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quanterix Releases Financial Results for the Third Quarter of 2026 Reports $35.0 million in revenue, up 6.3% sequentially, and $80.7 million of cash and marketable securities Initiatives to accelerate commercial effectiveness position the Company for growth in rest o

$QTRXHighAI 9/10

Quanterix (QTRX) Q2 2026 Earnings Call Transcript

Quanterix (QTRX) said Q2 2026 revenue was about $3 million (9%) below May guidance, citing broad-based shortfalls and commercial execution challenges. The company lowered 2026 revenue guidance to $142 million to $148 million from $169 million to $174 million and expects ~$80 million cash by year-end. Quanterix added commercial leaders (Jim Gute, Geoff Albrecht) and reorganized sales, citing Akoya integration savings of $85 million annually.

$QTRXMed

Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test

Quanterix (QTRX) said it completed Akoya Biosciences integration in Q2 and delivered $85M in revenue synergies. It is reshaping sales teams and expects clinical-trial bookings to rise QoQ. For its LucentAD Complete Alzheimer’s blood test, Quanterix filed a 510(k) in January and targets an FDA decision in Q4, possibly into Q1, citing a CMS price crosswalk of $897. It targets $10M diagnostics revenue in 2026.